On the other hand, ESI-09, the second inhibitor discussed, is a pan-EPAC competitive inhibitor that has demonstrated significant pharmacological effect in preventing the invasion and metastasis of pancreatic and breast cancers, as well as providing protection from fatal rickettsioses [24,68]. Here, RAPGEF3 is linked to breast carcinoma.